$59.61
0.82% today
NYSE, Feb 05, 04:16 pm CET
ISIN
US1101221083
Symbol
BMY
Sector
Industry

Bristol-Myers Squibb Stock price

$59.12
+2.44 4.30% 1M
+11.53 24.23% 6M
+2.56 4.53% YTD
+11.14 23.22% 1Y
-5.87 9.03% 3Y
-5.17 8.04% 5Y
-0.12 0.20% 10Y
NYSE, Closing price Tue, Feb 04 2025
-0.83 1.38%
ISIN
US1101221083
Symbol
BMY
Sector
Industry

Key metrics

Market capitalization $119.91b
Enterprise Value $163.27b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 11.83
EV/Sales (TTM) EV/Sales 3.44
P/S ratio (TTM) P/S ratio 2.53
P/B ratio (TTM) P/B ratio 6.99
Dividend yield 4.09%
Last dividend (FY24) $2.42
Revenue growth (TTM) Revenue growth 5.56%
Revenue (TTM) Revenue $47.44b
EBIT (operating result TTM) EBIT $8.36b
Free Cash Flow (TTM) Free Cash Flow $13.80b
Cash position $8.10b
EPS (TTM) EPS $-3.60
P/E forward negative
P/S forward 2.52
EV/Sales forward 3.44
Short interest 1.36%
Show more

Is Bristol-Myers Squibb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Bristol-Myers Squibb Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Bristol-Myers Squibb forecast:

10x Buy
34%
18x Hold
62%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Bristol-Myers Squibb forecast:

Buy
34%
Hold
62%
Sell
3%

Financial data from Bristol-Myers Squibb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
47,435 47,435
6% 6%
100%
- Direct Costs 20,935 20,935
12% 12%
44%
26,500 26,500
1% 1%
56%
- Selling and Administrative Expenses - -
- Research and Development Expense 9,818 9,818
6% 6%
21%
18,504 18,504
2% 2%
39%
- Depreciation and Amortization 10,145 10,145
3% 3%
21%
EBIT (Operating Income) EBIT 8,359 8,359
7% 7%
18%
Net Profit -7,258 -7,258
188% 188%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Bristol-Myers Squibb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bristol-Myers Squibb Stock News

Positive
The Motley Fool
2 days ago
If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive.
Neutral
Business Wire
5 days ago
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Opdivo plus Yervoy as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced HCC.
Neutral
Business Wire
5 days ago
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.
More Bristol-Myers Squibb News

Company Profile

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Head office United States
CEO Christopher Boerner
Employees 34,100
Founded 1933
Website www.bms.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today